Cannabidiol shows promise in treating cognitive disorders

Research reviews the therapeutic potential of cannabidiol (CBD) in treating cognitive impairments, highlighting positive effects in some trials while emphasizing the need for more comprehensive studies.

Drug pricing and the ‘impossible trinity’ for patients

You don’t have to be an economist to understand the law of demand: The higher the price, the less likely a customer is to buy

July 24, 2023

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update – Biotech Investments

Issuer: CureVac / Key word(s): Annual Results 24.04.2024 / 13:06 CET/CEST The issuer is solely responsible for the content of this announcement. CureVac Announces Financial

April 25, 2024

Sanofi’s eczema drug hits primary endpoint in PhIIb trial, plans underway for PhIII in 2024

Sanofi’s anti-OX40L antibody, amlitelimab, passed a 390-patient Phase IIb trial by hitting the primary endpoint, with patients seeing up to a 61.5% improvement on a

October 14, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.